T. Rowe Price T. Rowe Price Trusty Logo

Price Point - In Brief

U.S. Equities Flashing Yellow as Challenges Mount

Jeff Rottinghaus, Portfolio Manager in the U.S. Equity Division of T. Rowe Price.

Executive Summary

  • The environment for U.S. equities should remain supportive but is likely to become more challenging over the next year.
  • The rate of growth in corporate earnings should decelerate to about 8% to 10% from this year’s stunning rise.
  • Monetary tightening on a global basis may be a bigger concern than just the Federal Reserve raising rates.
  • Equity valuations vary widely by sector, but we are likely to see some compression in price/earnings ratios.
  • Uncertainty over tariffs and protectionist trade policies pose a significant threat to economic growth and individual companies.

Some of the tailwinds that have thrust U.S. equity markets to record highs in 2018 could become headwinds over the next year or so. While the environment should remain supportive for investing, it could become more challenging.

Corporate earnings have received a substantial boost from lower corporate tax rates, growing at a stunning 18% to 21% this year. However, the rate of growth is expected to decelerate next year to perhaps 8% to 10%. That would still be favorable by historical standards, but this lower rate is probably not being priced into markets now. High profit margins are also likely to face headwinds from higher rates, wages, and input costs.

The U.S. economy, buoyed by tax reform and deregulation policies, is strong. Manufacturing has reached new highs, leading indicators are positive, and small business optimism and consumer confidence are favorable. However, we are in the later stages of this economic cycle with less accommodative monetary policies, higher interest rates, and inflation and labor costs rising amid tighter labor markets. The uncertainty over tariffs and protectionist trade policies could also have an adverse impact on growth. And the stimulus from the tax cuts will have less impact next year. Recession risks are still moderate but rising.

Opening Quote While investors should probably lower their expectations, markets could continue to perform well if there is resolution on geopolitical issues in general and trade disputes in particular. Closing Quote

The Federal Reserve is likely to continue pushing short-term interest rates higher while other central banks in Japan and Europe moderate their very stimulative quantitative easing programs. Monetary tightening on a global basis could be a bigger story for the markets than the Fed raising rates because that global liquidity has been such a huge support in recent years.

Further, with longer-term interest rates fairly stable, the yield curve has been flattening and we could see it invert early next year, with short-term rates exceeding longer-term rates. That’s typically been a harbinger for a slower economy and weaker markets.

Another concern is that tax reform has not led to the boom in capital spending that many expected. Instead, many companies have deployed revenue growth into significant dividend increases and enormous share buyback activity. A stronger capex cycle would be beneficial for earnings.

U.S. equity valuations, meanwhile, vary widely by sector but have generally been above historical averages. We are likely to see some compression in price/earnings multiples next year.

FIGURE 1: S&P 500 Corporate Earnings Growth
Quarterly operating earnings per share growth, year-over-year as of September 2018 

Past performance is not a reliable indicator of future performance.
* Denotes consensus estimated earnings.
Source: S&P Dow Jones. 

Perhaps the biggest threat facing investors is the uncertainty over the trade tensions and tariffs imposed or threatened by the Trump administration as it seeks more favorable trade agreements with other countries. The heavy tariffs on China could end up being very disruptive to the economy and individual companies. As companies incur higher costs in their global supply chains, that leads to margin pressure on goods they manufacture or sell.

For example, we have typically maintained an overweight position in medical technology, which has performed well recently, but we’ve trimmed that position because the companies are susceptible to retaliatory tariffs imposed by China on their exports to that country. 

It is also noteworthy that the current U.S. equity bull market in August became the longest bull market in history—surpassing the run in the 1990s. Since 1958, it has also surpassed all but one other bull market in appreciation.

While investors should probably lower their expectations, markets could continue to perform well if there is resolution on geopolitical issues in general and trade disputes in particular. 

FIGURE 2: Forward Price-to-Earnings (P/E) Ratios
September 2003 through August 2018 

Source: T. Rowe Price calculations using data from FactSet Research Systems Inc. All rights reserved.
Frank Russell Company (Russell) is the source and owner of the Russell index data contained or reflected in these materials and all trademarks and copyrights related thereto. Russell® is a registered trademark of Russell. Russell is not responsible for the formatting or configuration of these materials or for any inaccuracy in T. Rowe Price Associates’ presentation thereof. 


Our largest sector allocations are information technology, health care, and financials—accounting for almost 60% of portfolio assets as of June 30, 2018. The technology sector, of course, has been dominated by a handful of fast-growing, mega-cap companies able to leverage dominant Internet platforms, such as Apple, Google, Microsoft, and Amazon. I expect these companies have the potential to remain powerful and continue to grow given their competitive advantages.

However, we trimmed technology holdings this year based on valuation and the regulatory risk stemming from data breaches, which poses our biggest concern for this sector. As a result, technology is actually our biggest underweight, accounting for about 22% of the portfolio compared with 26% for the S&P 500 Stock Index.

We remain optimistic on health care because, over the long term, it provides the best combination of solid fundamentals and acceptable valuations and is secularly driven by the aging population. And health care is becoming more global. China is buying more health care from the U.S. than ever before, in terms of both pharmaceuticals and medical technology. 

Opening Quote We remain optimistic on health care because, over the long term, it provides the best combination of solid fundamentals and acceptable valuations and is secularly driven by the aging population. Closing Quote

We recently began investing in pharmaceutical companies because that sector has materially underperformed, but now valuations are extremely attractive.

In the financials sector, where we are overweight the market, we have owned some of the higher-quality banks, which should benefit from rising rates. We have also had an overweight position in insurance brokers that have attractive business models, modest pricing power, and highly recurring revenue streams.

Also, considering the late stage of the economic cycle, we have invested in utilities. They typically are less volatile than the market and have some attractive secular themes, such as the huge growth in renewable energy in the United States.

We maintain our cautious view of the market overall, but stock selection will be the primary driver of longer-term performance. 

Important Information
The specific securities identified and described above do not necessarily represent securities purchased, sold or recommended by T. Rowe Price. This information is not intended to be a recommendation to take any particular investment action and is subject to change.

This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, and prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.

It is not intended for distribution to retail investors in any jurisdiction.

USA—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

© 2018 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.


Tap to dismiss


Latest Date Range
Audience for the document: Share Class: Language of the document:
Download Cancel


Share Class: Language of the document:
Download Cancel
Sign in to manage subscriptions for products, insights and email updates.
Continue with sign in?
To complete sign in and be redirected to your registered country, please select continue. Select cancel to remain on the current site.
Continue Cancel
Once registered, you'll be able to start subscribing.

Change Details

If you need to change your email address please contact us.
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®). TRP has been independently verified for the twenty one- year period ended June 30, 2017 by KPMG LLP. The verification report is available upon request. Verification assesses whether (1) the firm has complied with all the composite construction requirements of the GIPS standards on a firm-wide basis and (2) the firm's policies and procedures are designed to calculate and present performance in compliance with the GIPS standards. Verification does not ensure the accuracy of any specific composite presentation.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest